Cell Therapeutics’ Adaptive Trials For Lymphoma Treatment Pixantrone Could Meet Endpoints Early
This article was originally published in The Pink Sheet Daily
Executive Summary
Meeting endpoints early would allow NDA filing in second half of 2008, CEO James Bianco tells “The Pink Sheet” DAILY.